Lantern Pharma Inc. financial data

Symbol
LTRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1920 Mckinney Avenue, 7 Th Floor, Dallas, TX
State of incorporation
TX
Fiscal year end
December 31
Former names
Lantern Pharma (to 1/14/2019)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 998 % -49%
Debt-to-equity 11.2 % +102%
Return On Equity -56.9 % -89.9%
Return On Assets -51.2 % -80.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares -0.78%
Common Stock, Shares, Outstanding 10.8M shares -0.78%
Entity Public Float 52.6M USD +3.07%
Common Stock, Value, Issued 1.08K USD -0.83%
Weighted Average Number of Shares Outstanding, Basic 10.8M shares -0.87%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares -0.87%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.4M USD +45.9%
General and Administrative Expense 5.77M USD -7.77%
Operating Income (Loss) -21.2M USD -26%
Net Income (Loss) Attributable to Parent -19.1M USD -26%
Earnings Per Share, Basic -1.77 USD/shares -26.4%
Earnings Per Share, Diluted -1.77 USD/shares -44.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.1M USD -68.3%
Marketable Securities, Current 20M USD +3.09%
Assets, Current 29.9M USD -36.9%
Property, Plant and Equipment, Net 48.9K USD -4.1%
Operating Lease, Right-of-Use Asset 287K USD +6.7%
Other Assets, Noncurrent 36.7K USD +42%
Assets 30.3M USD -36.6%
Liabilities, Current 3.6M USD +59.8%
Operating Lease, Liability, Noncurrent 94K USD -11.8%
Liabilities 3.7M USD +56.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -25.3K USD +81.8%
Retained Earnings (Accumulated Deficit) -70.2M USD -37.4%
Stockholders' Equity Attributable to Parent 26.6M USD -41.4%
Liabilities and Equity 30.3M USD -36.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.07M USD +18.3%
Net Cash Provided by (Used in) Financing Activities 54.7K USD
Net Cash Provided by (Used in) Investing Activities -556K USD +42.1%
Common Stock, Shares Authorized 25M shares 0%
Common Stock, Shares, Issued 10.8M shares -0.78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.58M USD +24.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.2M USD -42%
Deferred Tax Assets, Valuation Allowance 12.5M USD +36.6%
Deferred Tax Assets, Gross 12.5M USD +36.6%
Operating Lease, Liability 291K USD +6.09%
Payments to Acquire Property, Plant, and Equipment 2.22K USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid 314K USD +7.66%
Operating Lease, Liability, Current 197K USD +17.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54.7K USD -12.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 205K USD +11.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +27.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22.9K USD +32.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.38M USD +14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 45K USD +7.14%
Additional Paid in Capital 96.8M USD +0.17%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 120K USD
Depreciation, Depletion and Amortization 4.06K USD +18.8%
Deferred Tax Assets, Net of Valuation Allowance 3.85K USD +5.16%
Operating Leases, Future Minimum Payments, Due in Three Years 53.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%